← back to search

Fen‐Biao Gao

University of Massachusetts Chan Medical School · US
Area of research
Neurology · Genetics
Research interest
Research interests include Amyotrophic Lateral Sclerosis Research, Neurogenetic and Muscular Disorders Research, RNA Research and Splicing, and Alzheimer's disease research and treatments.
h-index
64
citations
25,141
works
158
NIH funding
primary concept
email

Recent publications

Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
Neurology and Therapy 2023cited by 32position: middledoi
Translation of dipeptide repeat proteins in C9ORF72 ALS/FTD through unique and redundant AUG initiation codons
eLife 2023cited by 14position: middledoi
CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro
Nature Communications 2022cited by 69position: middledoi
p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR)
Cell 2021cited by 168position: middledoi
A C. elegans model of C9orf72-associated ALS/FTD uncovers a conserved role for eIF2D in RAN translation
Nature Communications 2021cited by 49position: middledoi
Ribosome profiling reveals novel regulation of <i>C9ORF72</i> GGGGCC repeat-containing RNA translation
RNA 2021cited by 29position: middledoi
Altered MICOS Morphology and Mitochondrial Ion Homeostasis Contribute to Poly(GR) Toxicity Associated with C9-ALS/FTD
Cell Reports 2020cited by 48position: middledoi
C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo
Nature Neuroscience 2019cited by 233position: lastdoi
CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)n Repeat-Associated Non-AUG Translation
Neuron 2019cited by 142position: middledoi
Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in <i>C9ORF72</i> -ALS/FTD
Proceedings of the National Academy of Sciences 2019cited by 88position: lastdoi
Context-Dependent and Disease-Specific Diversity in Protein Interactions within Stress Granules
Cell 2018cited by 951position: middledoi
Rethinking Unconventional Translation in Neurodegeneration
Cell 2017cited by 69position: firstdoi
Poly(GR) in C9ORF72 -Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons
Neuron 2016cited by 423position: lastdoi
Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability
Stem Cell Reports 2016cited by 109position: middledoi
Autophagy in neurodegenerative diseases
Brain Research 2016cited by 11position: lastdoi
GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport
Nature 2015cited by 867position: middledoi
Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice
Neuron 2015cited by 257position: middledoi
Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia
Nature Medicine 2014cited by 183position: lastdoi
Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons
Acta Neuropathologica 2013cited by 327position: lastdoi
Dissociation of Frontotemporal Dementia–Related Deficits and Neuroinflammation in Progranulin Haploinsufficient Mice
Journal of Neuroscience 2013cited by 181position: middledoi
Downregulation of MicroRNA-9 in iPSC-Derived Neurons of FTD/ALS Patients with TDP-43 Mutations
PLoS ONE 2013cited by 139position: lastdoi
Induced Pluripotent Stem Cell Models of Progranulin-Deficient Frontotemporal Dementia Uncover Specific Reversible Neuronal Defects
Cell Reports 2012cited by 135position: middledoi
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
Alzheimer s & Dementia 2012cited by 76position: middledoi
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)
Alzheimer s & Dementia 2012cited by 55position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sandra Almeida · University of Massachusetts Chan Medical School9 papers (2012–2021)Bruce L. Miller · University at Buffalo, State University of New York6 papers (2012–2016)Gopinath Krishnan · University of Massachusetts Chan Medical School5 papers (2019–2023)Zhijun Zhang · Nantong University4 papers (2012–2016)Anna Karydas · University of California, San Francisco4 papers (2012–2016)Leonard Petrucelli · Mayo Clinic4 papers (2013–2016)Robert V. Farese · Memorial Sloan Kettering Cancer Center3 papers (2012–2013)Dejun Yang · Neurological Surgery3 papers (2016–2019)Tania F. Gendron · Mayo Clinic in Florida3 papers (2013–2021)Soojin Lee · McGill University Health Centre3 papers (2019–2023)Yubing Lu · Xizang Minzu University3 papers (2013–2016)Giovanni Coppola · Regeneron (United States)3 papers (2012–2019)William W. Seeley · Hammersmith Hospital3 papers (2013–2019)So Yoen Choi · University of Massachusetts Chan Medical School2 papers (2019–2019)Yuanzheng Gu · The Ohio State University2 papers (2021–2023)Danqiong Sun · Gladstone Institutes2 papers (2013–2014)Maria Carmela Tartaglia · University Health Network2 papers (2012–2013)Daniel H. Geschwind · University of Southern California2 papers (2012–2016) · 2 papers (2018–2021)Hélène Tran · University of Massachusetts Chan Medical School2 papers (2013–2016)